title: Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer.
abstract: Orderly progression through the cell cycle requires sequential activation and inactivation of cyclin-dependent kinases (cdks). This is achieved in part through the association of cdks with positive regulators called cyclins and inactivation of cyclin-cdk complexes by a rapidly growing number of cyclin-cdk inhibitors. Recently, the role of cell cycle control proteins both as primary effectors and as mediators of tumorigenesis has become a subject of increased interest. Here we report the chromosomal mapping of two cdks, cdk3 and cdk6, two putative cdks, PISSLRE and PITALRE, and one cyclin-dependent kinase inhibitor, p27, to chromosomal regions which may be altered in human tumors and examine their possible involvement in some of these malignancies. In particular, two of the kinases, cdk3 and PISSLRE and PITALRE, the cdc2-related kinases recently cloned by us, map to regions previously shown to exhibit loss of heterozygosity in breast and other tumors.
authors.affiliation: Jefferson Cancer Insititute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107.
authors.forename: F
authors.initials: F
authors.lastname: Bullrich
authors.forename: T K
authors.initials: TK
authors.lastname: MacLachlan
authors.forename: N
authors.initials: N
authors.lastname: Sang
authors.forename: T
authors.initials: T
authors.lastname: Druck
authors.forename: M L
authors.initials: ML
authors.lastname: Veronese
authors.forename: S L
authors.initials: SL
authors.lastname: Allen
authors.forename: N
authors.initials: N
authors.lastname: Chiorazzi
authors.forename: A
authors.initials: A
authors.lastname: Koff
authors.forename: K
authors.initials: K
authors.lastname: Heubner
authors.forename: C M
authors.initials: CM
authors.lastname: Croce
mesh_terms: D001483:Base Sequence; D016203:CDC2 Protein Kinase / Q000235:genetics*; D002874:Chromosome Mapping; D051361:Cyclin-Dependent Kinase 6; D042863:Cyclin-Dependent Kinase 9; D050759:Cyclin-Dependent Kinase Inhibitor p21; D018844:Cyclin-Dependent Kinases; D016213:Cyclins / Q000235:genetics*; D006801:Humans; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000235:genetics*; D009687:Nuclear Proteins; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases / Q000235:genetics*; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D011518:Proto-Oncogene Proteins / Q000235:genetics; D051736:Proto-Oncogene Proteins c-mdm2
chemical_list: C493956:CDKN1A protein, human; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D009687:Nuclear Proteins; D047428:Protein Kinase Inhibitors; D011518:Proto-Oncogene Proteins; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2; D011494:Protein Kinases; D017346:Protein Serine-Threonine Kinases; D016203:CDC2 Protein Kinase; C501013:CDK10 protein, human; C495911:CDK6 protein, human; C467969:CDK9 protein, human; D051361:Cyclin-Dependent Kinase 6; D042863:Cyclin-Dependent Kinase 9; D018844:Cyclin-Dependent Kinases